LENZ Therapeutics, Inc. (NASDAQ:LENZ) saw its stock rise 6.1% in premarket trading following the release of its second-quarter financial report and confirmation that the FDA’s decision on its New Drug ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

When putting together your watch list, focus on stocks with an 80 or higher RS Rating. LENZ Therapeutics LENZ now meets that criteria, with a jump from 79 to 85 Friday. Please watch the video at ...

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

LENZ Therapeutics continues to make strong progress in its U.S. commercial preparations for LNZ100, its investigational treatment for presbyopia, as the Company approaches the August 8, 2025 PDUFA ...

LENZ Therapeutics’ product candidate addresses a widespread condition affecting approximately 1.8 billion people globally, highlighting the potential market size and opportunity for the company.

LENZ Therapeutics, Inc. and Lotus Pharmaceutical Co., Ltd. have entered into an exclusive licensing and commercialization agreement for LNZ100, an aceclidine-based eye drop intended to treat ...

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 Provided by GlobeNewswire Mar 11, 2025, 12:00:00 PM ...

Lenz Therapeutics said on Wednesday its lead experimental drug being tested in patients with a common age-related eye disorder showed improvement in nearsightedness in a late-stage study.